Results 11 to 20 of about 14,040 (225)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

Metabolites, 2023
Statins, the intestinal cholesterol transporter inhibitor (ezetimibe), and PCSK9 inhibitors can reduce serum LDL-C levels, leading to a significant reduction in cardiovascular events.
Shizuya Yamashita, Manfredi Rizzo, Ta-Chen Su, Daisaku Masuda   +3 more
doaj   +1 more source

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis

Hepatology, EarlyView., 2022
Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan, Yuhong Luo, Nana Yan, Keisuke Hamada, Nan Zhao, Yangliu Xia, Ping Wang, Changdong Zhao, Dan Qi, Shoumei Yang, Lulu Sun, Jie Cai, Qiong Wang, Changtao Jiang, Oksana Gavrilova, Kristopher W. Krausz, Daxesh P. Patel, Xiaoting Yu, Xuan Wu, Haiping Hao, Weiwei Liu, Aijuan Qu, Frank J. Gonzalez   +22 more
wiley   +1 more source

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

Hepatology, EarlyView., 2022
Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran, Charlotte Wilhelmina Wernberg, Mette Munk Lauridsen, Maria Kløjgaard Skytthe, Sofie Marchsteiner Bendixen, Frederik Tibert Larsen, Camilla Dalby Hansen, Lea Ladegaard Grønkjær, Majken Storm Siersbæk, Tina Di Caterino, Sönke Detlefsen, Holger Jon Møller, Lars Grøntved, Kim Ravnskjaer, Søren Kragh Moestrup, Maja Sofie Thiele, Aleksander Krag, Jonas Heilskov Graversen   +17 more
wiley   +1 more source

Association between triglyceride levels and cardiovascular disease in patients with acute pancreatitis. [PDF]

PLoS ONE, 2018
Conventional wisdom supports prescribing "fibrates before statins", that is, prioritizing treatment of hypertriglyceridemia (hTG) to prevent pancreatitis ahead of low-density lipoprotein cholesterol to prevent coronary heart disease.
Laurel A Copeland, C Scott Swendsen, Dawn M Sears, Andrea A MacCarthy, Catherine J McNeal   +4 more
doaj   +1 more source

Latent Fibrations: Fibrations for Categories of Partial Maps

Theory and Applications of Categories, 2021
65 pages, submitted to "Theory and Applications of Categories"
Cockett, Robin, Cruttwell, Geoff, Gallagher, Jonathan, Pronk, Dorette   +3 more
openaire   +3 more sources

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing

Annals of Medicine, 2022
Based on separate protective mechanisms related to lipid metabolism, viral cell entry and inflammation, fibrate treatment might be advantageous among patients who have been taking fibrates before SARS-CoV-2 infection and continue taking them during the ...
Alpo Vuorio, Jonas Brinck, Petri T. Kovanen   +2 more
doaj   +1 more source

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates

iScience, 2020
Summary: Most triacylglycerol-lowering fibrates have been developed in the 1960s–1980s before their molecular target, peroxisome proliferator-activated receptor alpha (PPARα), was identified.
Shotaro Kamata, Takuji Oyama, Kenta Saito, Akihiro Honda, Yume Yamamoto, Keisuke Suda, Ryo Ishikawa, Toshimasa Itoh, Yasuo Watanabe, Takahiro Shibata, Koji Uchida, Makoto Suematsu, Isao Ishii   +12 more
doaj   +1 more source

The Gödel Fibration

, 2021
39 ...
Davide Trotta, Matteo Spadetto, Valeria de Paiva   +2 more
openaire   +4 more sources

Use of fibrates is not associated with reduced risks of mortality or cardiovascular events among ESRD patients: A national cohort study

Frontiers in Cardiovascular Medicine, 2022
BackgroundAlthough a recent study reported that fibrates are associated with a low risk of cardiovascular (CV) death and can postpone the need for long-term hemodialysis in patients with advanced chronic kidney disease (CKD), little is known regarding ...
Wen-Yu Ho, Chieh-Li Yen, Chieh-Li Yen, Cheng-Chia Lee, Cheng-Chia Lee, Yi-Ran Tu, Yi-Ran Tu, Chao-Yu Chen, Chao-Yu Chen, Ching-Chung Hsiao, Ching-Chung Hsiao, Pao-Hsien Chu, Pao-Hsien Chu, Hsiang-Hao Hsu, Hsiang-Hao Hsu, Ya-Chun Tian, Ya-Chun Tian, Chih-Hsiang Chang, Chih-Hsiang Chang   +18 more
doaj   +1 more source

Lipid Messenger Phosphatidylinositol-4,5-Bisphosphate Is Increased by Both PPARα Activators and Inhibitors: Relevance for Intestinal Cell Differentiation

Biology, 2022
We investigated the effects of PPARα activators fenofibrate and WY-14643 as well as the PPARα inhibitor GW6471 on the PI3K/Akt/PTEN pathway of intestinal cell differentiation. Our previous study showed that all these compounds increased the expression of
Katerina Cizkova, Katerina Koubova, Zdenek Tauber   +2 more
doaj   +1 more source